Cancer Drugs– tag –
-
Series: Untangling Cancer Worries — Your First GuidePart 6: What Is a Rare Cancer? How to Search When Information Is Limited—and What to Ask Clinicians
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is a “... -
Oncology Drug Approval News Flash: Optune Pax, a low electric field tumor treating fields device, approved with gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p... -
Series: Untangling Cancer Worries — Your First GuidePart 5: Genetic Variants and Cancer Risk — What Tests Can Tell You (and What They Can’t)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Series: Untangling Cancer Worries — Your First Guide Part 4: Benign vs Malignant Tumors — What the Words Mean (and What to Confirm First)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Series: Untangling Cancer Worries — Your First Guide Part 3: What Does “Metastasis” Mean? How It Differs From Stage—and How Treatment Plans Can Change
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is met... -
Oncology Drug Approval News Flash: Pembrolizumab plus paclitaxel with or without bevacizumab approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with... -
The more important question than “present or absent”: how microbial elements may tune immunity in brain tumors
Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging environment to study. Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging... -
Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V... -
The Word “Vaccine” Breaks the Conversation: How Far Have Cancer Vaccines Actually Come?
The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infectious disease, and it also happens in ca... -
Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. This series places women’s cancer risk on a single life-course m... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 6)
Episode 6 | Lifestyle and Women’s Cancer Risk: Weight, Activity, Alcohol, and Sleep—A Practical Plan to Lower Risk Without Chasing Perfection Hormonal milestones (menarche, pregnancy, menopause) shape women’s cancer risk over decades. Ho... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 5)
Episode 5 | Perimenopause and Menopausal Symptoms: Balancing Cancer Risk, Quality of Life, and the Role of HRT Menopause is often described as “estrogen going down,” but lived experience is usually about something else: fluctuation. Meno... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 4
Episode 4 | Endometrial Cancer, Hormone Balance, and Metabolic Health: The “Unopposed Estrogen” Intersection “My hormones feel off” is a common phrase—useful, but often too vague to drive action. “My hormones feel off” is a common phrase... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Breast cancer is one of the most information-heavy topics in women... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 1
Episode 1 | A Life-Course Map of Female Hormones: From Puberty to Post-Menopause Women’s health topics are often discussed in separate “boxes”: symptoms (PMS, menstrual pain, menopause) on one side, and diseases (breast cancer, ovarian c... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column B – A Practical ADC Strategy Checklist: Ten Questions for Pharma, Biotechs, Investors, and Advisors
In Column B, we translate the themes of this series into a practical checklist for people who must make decisions about ADCs in their daily work: In Column B, we translate the themes of this series into a practical checklist for people w... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column A – How Enhertu Reshaped the ADC Landscape: A Case Study in Design, Clinical Strategy, and Business Impact
In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this series, and ask a simple but far-reaching question:Why did this part In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this seri... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—a In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into th... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we review In Part 1 of this series, we explored why the ADC land grab is happening now and how A...
